statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily ce (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 strokes per 10,000 women-years, respectively). the increase in risk was demonstrated in year 1 and persisted [see clinical studies ( 14.2 )] . immediately discontinue estrogen-alone therapy if a stroke occurs or is suspected. subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving ce (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years). 1 the whi estrogen plus progestin substudy reported a statistically significant increased risk of stroke in women 50 to 79 years of age receiving daily ce (0.625 mg) plus mpa (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 strokes per 10,000 women years, respectively) [see clinical studies ( 14.2 )] . the increase in risk was demonstrated after the first year and persisted. 1 immediately discontinue estrogen plus progestogen therapy if a stroke occurs or is suspected. coronary heart disease the whi estrogen-alone substudy reported no overall effect on coronary heart disease (chd) events (defined as nonfatal mi, silent mi, or chd death) in women receiving estrogen-alone compared to placebo 2 [see clinical studies ( 14.2 )] . subgroup analyses of women 50 to 59 years of age, who were less than 10 years since menopause, suggest a reduction (not statistically significant) of chd events in those women receiving daily ce (0.625 mg)-alone compared to placebo (8 versus 16 per 10,000 women-years). 1 the whi estrogen plus progestin substudy reported an increased risk (not statistically significant) of chd events in women receiving daily ce (0.625 mg) plus mpa (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). 1 an increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see clinical studies ( 14.2 )] . in postmenopausal women with documented heart disease (n = 2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (heart and estrogen/progestin replacement study; hers), treatment with daily ce (0.625 mg) plus mpa (2.5 mg) demonstrated no cardiovascular benefit. during an average follow-up of 4.1 years, treatment with ce plus mpa did not reduce the overall rate of chd events in postmenopausal women with established chd. there were more chd events in the ce plus mpa-treated group than in the placebo group in year 1, but not during the subsequent years. two thousand three hundred twenty-one (2,321) women from the original hers trial agreed to participate in an open label extension of hers, hers ii. average follow-up in hers ii was an additional 2.7 years, for a total of 6.8 years overall. rates of chd events were comparable among women in the ce plus mpa group and the placebo group in hers, hers ii, and overall. venous thromboembolism in the whi estrogen-alone substudy, the risk of vte (dvt and pe) was increased for women receiving daily ce (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of dvt reached statistical significance (23 versus 15 per 10,000 women-years). the increase in vte risk was demonstrated during the first 2 years 3 [see clinical studies ( 14.2 )] . immediately discontinue estrogen-alone therapy if vte occurs or is suspected. the whi estrogen plus progestin substudy reported a statistically significant 2-fold greater rate of vte in women receiving daily ce (0.625 mg) plus mpa (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). statistically significant increases in risk for both dvt (26 versus 13 per 10,000 women-years) and pe (18 versus 8 per 10,000 women-years) were also demonstrated. the increase in vte risk was demonstrated during the first year and persisted 4 [see clinical studies ( 14.2 )] . immediately discontinue estrogen plus progestogen therapy if a vte occurs or is suspected. if feasible, discontinue estrogens at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. 5.2 malignant neoplasms endometrial cancer an increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. the reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users and appears dependent on duration of treatment and on estrogen dose. most studies show no significant increased risk associated with use of estrogens for less than 1 year. the greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more, and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued. clinical surveillance of all women using estrogen-alone or estrogen plus progestogen therapy is important. perform adequate diagnostic measures, including directed or random endometrial sampling when indicated to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding with unknown etiology. there is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. adding a progestogen to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. breast cancer the whi substudy of daily ce (0.625 mg)-alone provided information about breast cancer in estrogen-alone users. in the whi estrogen-alone substudy, after an average follow-up of 7.1 years, daily ce (0.625mg)-alone was not associated with an increased risk of invasive breast cancer [relative risk (rr) 0.80] 5 [see clinical studies ( 14.2 )] . after a mean follow-up of 5.6 years, the whi substudy of daily ce (0.625 mg) plus mpa (2.5 mg) reported an increased risk of invasive breast cancer in women who took daily ce plus mpa compared to placebo. in this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. the relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for ce plus mpa compared with placebo [see clinical studies ( 14.2 )] . among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years for ce plus mpa compared with placebo. 6 among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for ce plus mpa compared with placebo. in the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the ce (0.625 mg) plus mpa (2.5 mg) group compared with the placebo group. metastatic disease was rare, with no apparent difference between the two groups. other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups 6 [see clinical studies ( 14.2 )] . consistent with the whi clinical trial, observational studies have also reported an increased risk of breast cancer with estrogen plus progestin therapy, and a smaller increase in the risk for breast cancer with estrogen-alone therapy, after several years of use. the risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. these studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration. the use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. all women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. in addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results. ovarian cancer the ce plus mpa substudy of whi reported that estrogen plus progestin increased the risk of ovarian cancer. after an average follow-up of 5.6 years, the relative risk for ce plus mpa versus placebo was 1.58 (95 percent ci, 0.77-3.24), but it was not statistically significant. the absolute risk for ce plus mpa versus placebo was 4 versus 3 cases per 10,000 women-years. 7 a meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. the primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. the relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [ci] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years]vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). the relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% ci 1.27 to 1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. the exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. 5.3 probable dementia in the whi memory study (whims) estrogen-alone ancillary study, a population of 2,947 hysterectomized women 65 to 79 years of age were randomized to daily ce (0.625 mg)-alone or placebo. after an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. the relative risk of probable dementia for ce-alone versus placebo was 1.49 (95 percent ci, 0.83-2.66). the absolute risk of probable dementia for ce-alone versus placebo was 37 versus 25 cases per 10,000 women-years 8 [see use in specific populations ( 8.5 ), and clinical studies ( 14.3 )] . in the whims estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily ce (0.625 mg) plus mpa (2.5 mg) or placebo. after an average follow-up of 4 years, 40 women in the ce plus mpa group and 21 women in the placebo group were diagnosed with probable dementia. the relative risk of probable dementia for ce plus mpa versus placebo was 2.05 (95 percent ci, 1.21-3.48). the absolute risk of probable dementia for ce plus mpa versus placebo was 45 versus 22 cases per 10,000 women-years 8 [see use in specific populations ( 8.5 ), and clinical studies ( 14.3 )] . when data from the two populations in the whims estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the whims protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent ci, 1.19-2.60). since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see use in specific populations ( 8.5 ), and clinical studies ( 14.3 )] . 5.4 gallbladder disease a 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported. 5.5 hypercalcemia estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases. discontinue estrogens, including menostar if hypercalcemia occurs, and take appropriate measures to reduce the serum calcium level. 5.6 visual abnormalities retinal vascular thrombosis has been reported in women receiving estrogens. discontinue menostar pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. permanently discontinue estrogens, including menostar, if examination reveals papilledema or retinal vascular lesions. 5.7 addition of a progestogen when a woman has not had a hysterectomy studies of the addition of a progestogen for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. endometrial hyperplasia may be a precursor to endometrial cancer. there are, however, possible risks that may be associated with the use of progestogens with estrogens compared to estrogen-alone regimens. these include an increased risk of breast cancer. 5.8 elevated blood pressure in a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. in a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen. 5.9 exacerbation of hypertriglyceridemia in women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. discontinue menostar if pancreatitis occurs. 5.10 hepatic impairment and/or past history of cholestatic jaundice estrogens may be poorly metabolized in women with hepatic impairment. exercise caution in any woman with a history of cholestatic jaundice associated with past estrogen use or with pregnancy. in the case of recurrence of cholestatic jaundice, discontinue menostar. 5.11 exacerbation of hypothyroidism estrogen administration leads to increased thyroid-binding globulin (tbg) levels. women with normal thyroid function can compensate for the increased tbg by making more thyroid hormone, thus maintaining free t 4 and t 3 serum concentrations in the normal range. women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. monitor thyroid function in these women during treatment with menostar to maintain their free thyroid hormone levels in an acceptable range. 5.12 fluid retention estrogens may cause some degree of fluid retention. monitor any woman with a condition(s) that might predispose her to fluid retention, such as a cardiac or renal impairment. discontinue estrogen-alone therapy, including menostar, with evidence of medically concerning fluid retention. 5.13 hypocalcemia estrogen-induced hypocalcemia may occur in women with hypoparathyroidism. consider whether the benefits of estrogen therapy, including menostar, outweigh the risks in such women. 5.14 exacerbation of endometriosis a few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. consider the addition of progestogen therapy for women known to have residual endometriosis post-hysterectomy. 5.15 hereditary angioedema exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. consider whether the benefits of estrogen therapy, including menostar, outweigh the risks in such women. 5.16 exacerbation of other conditions 5.17 laboratory tests serum follicle stimulating hormone (fsh) and estradiol levels have not been shown to be useful in the management of postmenopausal women using menostar for the prevention of postmenopausal osteoporosis. 5.18 drug-laboratory test interactions • accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors ii, vii antigen, viii antigen, viii coagulant activity, ix, x, xii, vii-x complex, ii-vii-x complex, and beta-thromboglobulin; decreased levels of antifactor xa and antithrombin iii, decreased antithrombin iii activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. • increased tbg levels leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (pbi), t 4 levels (by column or by radioimmunoassay) or t 3 levels by radioimmunoassay. t 3 resin uptake is decreased, reflecting the elevated tbg. free t 4 and free t 3 concentrations are unaltered. women on thyroid replacement therapy may require higher doses of thyroid hormone. • other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (cbg), sex hormone-binding globulin (shbg), leading to increased total circulating corticosteroids and sex steroids, respectively. free hormone concentrations, such as testosterone and estradiol, may be decreased. other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-l-antitrypsin, ceruloplasmin). • increased plasma high-density lipoprotein (hdl) and hdl 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (ldl) cholesterol concentration, and increased triglyceride levels. impaired glucose tolerance.

menostar transdermal system site selection • place the adhesive side of menostar on a clean, dry area of the lower abdomen or the upper quadrant of the buttock. • do not apply menostar to or near the breasts. • rotate the sites of application with an interval of at least 1-week allowed between applications to a same site. • select an area that is not oily, damaged, or irritated. avoid the waistline, since tight clothing may rub the transdermal system off. • avoid application to areas where sitting would dislodge menostar. application • apply menostar immediately after opening the pouch and removing the protective liner. • press menostar firmly in place with the fingers for at least 10 seconds, making sure there is good contact, especially around the edges. • if the system lifts, apply pressure to maintain adhesion. • in the event that a system falls off, reapply it to a different location. if the old system cannot be reapplied, apply a new system for the remainder of the 7-day dosing interval. • wear only one system at any one time during the 7-day dosing interval. • swimming, bathing, or using a sauna while using menostar has not been studied, and these activities may decrease the adhesion of the system and the delivery of estradiol. 2.3 removal of the menostar transdermal system • remove menostar carefully and slowly to avoid irritation of the skin. • if any adhesive remains on the skin after removal of menostar, allow the area to dry for 15 minutes and then gently rub the area with an oil-based cream or lotion to remove the adhesive residue. • used patches still contain some active hormones. carefully fold each patch in half so that it sticks to itself before throwing it away.

tal of 417 postmenopausal women (208 women on menostar, 209 on placebo) 60 to 80 years old, with an intact uterus were enrolled in the study. at 24 months, 189 women remained in the menostar group and 186 remained in the placebo group. adverse events with an incidence of ≥5 percent in the menostar 14 mcg group and greater than those reported in the placebo group are listed in table 1. table 1: summary of most frequently reported treatment emergent adverse reactions (≥5 percent) by treatment groups body system adverse reactions menostar 14 mcg/day (n=208) placebo (n=209) body as a whole 95 (46%) 100 (48%) abdominal pain 17 (8%) 17 (8%) accidental injury 29 (14%) 23 (11%) infection 11 (5%) 10 (5%) pain 26 (13%) 26 (12%) cardiovascular 20 (10%) 19 (9%) digestive system 52 (25%) 44 (21%) constipation 11 (5%) 6 (3%) dyspepsia 11 (5%) 9 (4%) metabolic and nutritional disorders 25 (12%) 22 (11%) musculoskeletal system 54 (26%) 51 (24%) arthralgia 24 (12%) 13 (6%) arthritis 11 (5%) 15 (7%) myalgia 10 (5%) 6 (3%) nervous system 30 (14%) 23 (11%) dizziness 11 (5%) 6 (3%) respiratory system 62 (30%) 67 (32%) bronchitis 12 (6%) 9 (4%) upper respiratory infection 33 (16%) 35 (17%) skin and appendages 50 (24%) 54 (26%) application site reaction 18 (9%) 18 (9%) breast pain 10 (5%) 8 (4%) urogenital system 66 (32%) 40 (19%) cervical polyps 13 (6%) 4 (2%) leukorrhea 22 (11%) 3 (1%) 6.2 postmarketing experience the following adverse reactions have been identified during post-approval use of climara and menostar. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. genitourinary system changes in bleeding pattern, pelvic pain breast breast cancer, breast pain, breast tenderness cardiovascular changes in blood pressure, palpitations, hot flashes gastrointestinal vomiting, abdominal pain, abdominal distension, nausea skin alopecia, hyperhidrosis, night sweats, urticaria, rash eyes visual disturbances, contact lens intolerance central nervous system depression, migraine, paresthesia, dizziness, anxiety, irritability, mood swings, nervousness, insomnia, headache miscellaneous edema, fatigue, menopausal symptoms, weight increased, application site reaction, anaphylactic reactions

menostar and any potential adverse effects on the breastfed child from menostar or from the underlying maternal condition. 8.4 pediatric use menostar is not indicated for use in pediatric patients. clinical studies have not been conducted in the pediatric population. 8.5 geriatric use a total of 417 postmenopausal women 61 to 79 years old, with an intact uterus, participated in the osteoporosis trial. more than 50 percent of women receiving study drug, were 65 years of age or older. efficacy in older (≥ 65 years of age) and younger (<65 years of age) postmenopausal women in the osteoporosis treatment trial was comparable both at 12 and 24 months. safety in older (≥ 65 years of age) and younger (<65 years of age) postmenopausal women in the osteoporosis treatment trial was also comparable throughout the study. the women’s health initiative studies in the whi estrogen-alone substudy (daily ce [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies ( 14.2 )] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies ( 14.2 )] . the women’s health initiative memory study in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions ( 5.3 ), and clinical studies ( 14.3 )] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women 8 [see warnings and precautions ( 5.3 ), and clinical studies ( 14.3 )].

sponsive tissues. to date, two estrogen receptors have been identified. these vary in proportion from tissue to tissue. circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (lh) and follicle stimulating hormone (fsh), through a negative feedback mechanism. estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. 12.2 pharmacodynamics generally, a serum estrogen concentration does not predict an individual woman’s therapeutic response to menostar nor her risk for adverse outcomes. likewise, exposure comparisons across different estrogen products to infer efficacy or safety for the individual woman may not be valid. 12.3 pharmacokinetics absorption the bioavailability of estradiol following application of a menostar transdermal system, relative to that of a transdermal system delivering 25 mcg per day, was investigated in 18 healthy postmenopausal women, mean age 66 years (range 60 to 80 years). the mean serum estradiol concentrations upon administration of the two patches to the lower abdomen are shown in figure 1. transdermal administration of menostar produced geometric mean serum concentration (c avg ) of estradiol of 13.7 pg/ml. no patches failed to adhere during the one week application period of both transdermal systems. following application of the menostar transdermal system to the abdomen, it is estimated to provide an average nominal in-vivo daily delivery of 14 mcg estradiol per day. the menostar transdermal delivery system continuously releases estradiol which is transported across intact skin leading to sustained circulating levels of estradiol during a 7-day treatment period. the systemic availability of estradiol after transdermal administration is about 20 times higher than that after oral administration. this difference is due to the absence of first pass metabolism when estradiol is given by the transdermal route. figure 1: mean uncorrected serum 17ß-estradiol concentrations vs. time profile following application of the menostar transdermal system and the climara® 6.5 cm2 transdermal system table 2 provides a summary of estradiol pharmacokinetic parameters determined during evaluation of the menostar transdermal system using baseline uncorrected serum concentrations. table 2: summary of estradiol pharmacokinetic parameters (abdomen application) product estradiol daily delivery rate, mcg/day auc (0-t last ) pg•h/ml c max pg/ml c avg pg/ml t max h c min pg/ml menostar 14 2296 20.6 13.7 42 12.6 climara 6.5 cm 2 25 4151 37.2 24.7 42 20.4 pharmacokinetic parameters are expressed in geometric means except for the t max which represents the median estimate and the c min which is expressed as the arithmetic mean. the estimated estradiol daily delivery rate for climara 6.5 cm 2 is quoted from the climara labeling. distribution the distribution of exogenous estrogens is similar to that of endogenous estrogens. estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. estrogens circulate in the blood largely bound to shbg and albumin. in the clinical study with 208 patients on menostar, shbg concentration (mean ± sd) remained essentially unchanged over the 2 year period (baseline 45.1 ± 20.1 nmol/l, 24-month visit 46.4 ± 20.9 nmol/l). metabolism exogenous estrogens are metabolized in the same manner as endogenous estrogens. circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. these transformations take place mainly in the liver. estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. in postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. excretion estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. adhesion in a menostar transdermal system pharmacokinetic study with 18 postmenopausal women, no patches failed to adhere during the one-week application period. figure 1

stemic availability of estradiol after transdermal administration is about 20 times higher than that after oral administration. this difference is due to the absence of first pass metabolism when estradiol is given by the transdermal route. figure 1: mean uncorrected serum 17ß-estradiol concentrations vs. time profile following application of the menostar transdermal system and the climara® 6.5 cm2 transdermal system table 2 provides a summary of estradiol pharmacokinetic parameters determined during evaluation of the menostar transdermal system using baseline uncorrected serum concentrations. table 2: summary of estradiol pharmacokinetic parameters (abdomen application) product estradiol daily delivery rate, mcg/day auc (0-t last ) pg•h/ml c max pg/ml c avg pg/ml t max h c min pg/ml menostar 14 2296 20.6 13.7 42 12.6 climara 6.5 cm 2 25 4151 37.2 24.7 42 20.4 pharmacokinetic parameters are expressed in geometric means except for the t max which represents the median estimate and the c min which is expressed as the arithmetic mean. the estimated estradiol daily delivery rate for climara 6.5 cm 2 is quoted from the climara labeling. distribution the distribution of exogenous estrogens is similar to that of endogenous estrogens. estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. estrogens circulate in the blood largely bound to shbg and albumin. in the clinical study with 208 patients on menostar, shbg concentration (mean ± sd) remained essentially unchanged over the 2 year period (baseline 45.1 ± 20.1 nmol/l, 24-month visit 46.4 ± 20.9 nmol/l). metabolism exogenous estrogens are metabolized in the same manner as endogenous estrogens. circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. these transformations take place mainly in the liver. estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. in postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. excretion estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. adhesion in a menostar transdermal system pharmacokinetic study with 18 postmenopausal women, no patches failed to adhere during the one-week application period. figure 1

after 1 and 2 years (table 3). table 3: mean percent bmd change from baseline in lumbar spine and total hip (full analysis set) lumbar spine total hip time points menostar na = 208 placebo na = 209 p-value time points menostar na = 208 placebo na = 209 p-value nb = 189 nb = 186 nb = 189 nb =184 12-month endpoint +2.29 +0.51 < 0.001 12-month endpoint +0.90 -0.22 < 0.001 nb = 189 nb = 186 nb = 189 nb = 185 24-month endpoint +2.99 +0.54 < 0.001 24-month endpoint +0.84 -0.71 < 0.001 a) n = total number of patients. b) n = number of patients with data available for each variable. the bmd data of the study were analyzed according to baseline estradiol levels of the patients. overall, estimated treatment effects on lumbar spine and total hip bmd after 2 years were approximately twice as large in the subgroup with baseline estradiol levels < 5 pg/ml than in the subgroup with baseline estradiol levels ≥ 5 pg/ml (table 4). table 4: mean percent change in lumbar spine and total hip bmd at 24 months by subgroups of baseline estradiol level (< 5 pg/ml, 5 pg/ml) lumbar spine total hip baseline estradiol levels menostar placebo treatment difference menostar placebo treatment difference < 5 pg/ml na = 101 na = 97 na = 101 na = 96 +3.50 +0.29 3.21 +1.04 -1.09 2.13 (p < 0.001) (p < 0.001) ≥ 5 pg/ml na = 88 na = 89 na = 88 na = 89 +2.40 +0.81 1.59 +0.61 -0.31 0.92 (p = 0.002) (p = 0.045) a) n = number of patients with data available for each variable. 14.2 women's health initiative studies table 5: relative and absolute risk seen in the estrogen-alone substudy of whi a event b relative risk ce vs. placebo (95% nci b ) ce n = 5,310 placebo n = 5,429 absolute risk per 10,000 women-years chd events c 0.95 (0.78-1.16) 54 57 non-fatal mi c 0.91 (0.73-1.14) 40 43 chd death c 1.01 (0.71-1.43) 16 16 all strokes c 1.33 (1.05-1.68) 45 33 ischemic stroke c 1.55 (1.19-2.01) 38 25 deep vein thrombosis c,d 1.47 (1.06-2.06) 23 15 pulmonary embolism c 1.37 (0.90-2.07) 14 10 invasive breast cancer c 0.8 (0.62-1.04) 28 34 colorectal cancer c 1.08 (0.75-1.55) 17 16 hip fracture c 0.65 (0.45-0.94) 12 19 vertebral fractures c,d 0.64 (0.44-0.93) 11 18 lower arm/wrist fractures c,d 0.58 (0.47-0.72) 35 59 total fractures c,d 0.71 (0.64-0.80) 144 197 death due to causes e,f 1.08 (0.88-1.32) 53 50 overall mortality c,d 1.04 (0.88-1.22) 79 75 global indexg 1.02 (0.92-1.13) 206 201 a) adapted from numerous whi publications. whi publications can be viewed at www.nhlbi.nih.gov/whi. b) nominal confidence intervals unadjusted for multiple looks and multiple comparisons. c) results are based on centrally adjudicated data for an average follow-up of 7.1 years. d) not included in “global index”. e) results are based on an average follow-up of 6.8 years. f) all deaths, except from breast or colorectal cancer, definite or probable chd, pe or cerebrovascular disease. g) a subset of the events was combined in a "global index", defined as the earliest occurrence of chd events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. for those outcomes included in the whi "global index" that reached statistical significance, the absolute excess risks per 10,000 women-years in the group treated with ce-alone was 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures. 9 the absolute excess risk of events included in the "global index" was a non-significant 5 events per 10,000 women-years. there was no difference between the groups in terms of all-cause mortality. no overall difference for primary chd events (nonfatal mi, silent mi and chd death) and invasive breast cancer incidence in women receiving ce-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years. see table 5. centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in the distribution of stroke subtype and severity, including fatal strokes, in women receiving estrogen-alone compared to placebo. estrogen-alone increased the risk of ischemic stroke, and this excess risk was present in all subgroups of women examined. 10 see table 5. timing of initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile. the whi estrogen-alone substudy stratified by age showed in women 50 to 59 years of age a non-significant trend toward reduced risk for chd [hazard ratio (hr) 0.63 (95 percent ci, 0.36-1.09)] and overall mortality [hr 0.71 (95 percent ci, 0.46-1.11)] . whi estrogen plus progestin substudy the whi estrogen plus progestin substudy was stopped early. according to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the "global index". the absolute excess risk of events included in the “global index” was 19 per 10,000 women-years. for those outcomes included in the whi “global index” that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with ce plus mpa were 7 more chd events, 8 more strokes, 10 more pes, and 8 more invasive breast cancers, while the absolute risk reduction per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures. results of the ce plus mpa substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent white, 6.5 percent black, 5.4 percent hispanic, 3.9 percent other), are presented in table 6. these results reflect table 6: relative and absolute risk seen in the estrogen plus progestin substudy of whi at an average of 5.6 years a,b event relative risk ce/mpa vs. placebo (95% ncic) ce/mpa n = 8,506 placebo n = 8,102 absolute risk per 10,000 women-years chd events 1.23 (0.99-1.53) 41 34 non-fatal mi 1.28 (1.00-1.63) 31 25 chd death 1.10 (0.70-1.75) 8 8 all strokes 1.31 (1.03-1.68) 33 25 ischemic stroke 1.44 (1.09-1.90) 26 18 deep vein thrombosis d 1.95 (1.43-2.67) 26 13 pulmonary embolism 2.13 (1.45-3.11) 18 8 invasive breast cancer e 1.24 (1.01-1.54) 41 33 colorectal cancer 0.61 (0.42-0.87) 10 16 endometrial cancer d 0.81 (0.48-1.36) 6 7 cervical cancer d 1.44 (0.47-4.42) 2 1 hip fracture 0.67 (0.47-0.96) 11 16 vertebral fractures d 0.65 (0.46-0.92) 11 17 lower arm/wrist fractures d 0.71 (0.59-0.85) 44 62 total fractures d 0.76 (0.69-0.83) 152 199 overall mortality f 1.00 (0.83-1.19) 52 52 global indexg 1.13 (1.02-1.25) 184 165 a) adapted from numerous whi publications. whi publications can be viewed at www.nhlbi.nih.gov/whi. b) results are based on centrally adjudicated data. c) nominal confidence intervals unadjusted for multiple looks and multiple comparisons. d) not included in “global index”. e) includes metastatic and non-metastatic breast cancer, with the exception of in situ breast cancer. f) all deaths, except from breast or colorectal cancer, definite or probable chd, pe or cerebrovascular disease. g) a subset of the events was combined in a "global index”, defined as the earliest occurrence of chd events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. timing of initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. the whi estrogen plus progestin substudy stratified by age showed in women 50 to 59 years of age a non-significant trend toward reduced risk for overall mortality [hr 0.69 (95 percent ci 0.44-1.07)] . 14.3 women's health initiative memory study the whims estrogen-alone ancillary study of whi enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age and older (45 percent were 65 to 69 years of age; 36 percent were 70 to 74 years of age; 19 percent were 75 years of age and older) to evaluate the effects of daily ce (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo. after an average follow-up of 5.2 years, the relative risk of probable dementia for ce-alone versus placebo was 1.49 (95 percent ci, 0.83-2.66). the absolute risk of probable dementia for ce-alone versus placebo was 37 versus 25 cases per 10,000 women-years. probable dementia as defined in the study included alzheimer’s disease (ad), vascular dementia (vad) and mixed types (having features of both ad and vad). the most common classification of probable dementia in the treatment group and the placebo group was ad. since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see warnings and precautions ( 5.3 ), and use in specific populations ( 8.5 )] . the whims estrogen plus progestin ancillary study enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age; 35 percent were 70 to 74 years of age; and 18 percent were 75 years of age and older) to evaluate the effects of daily ce (0.625 mg) plus mpa (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo. after an average follow-up of 4 years, the relative risk of probable dementia for ce plus mpa versus placebo was 2.05 (95 percent ci, 1.21-3.48). the absolute risk of probable dementia for ce plus mpa versus placebo was 45 versus 22 cases per 10,000 women-years. probable dementia as defined in the study included ad, vad and mixed types (having features of both ad and vad). the most common classification of probable dementia in the treatment group and the placebo group was ad. since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see warnings and precautions ( 5.3 ), and use in specific populations ( 8.5 )] . when data from the two populations were pooled as planned in the whims protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent ci, 1.19-2.60). differences between groups became apparent in the first year of treatment. it is unknown whether these findings apply to younger postmenopausal women [see warnings and precautions ( 5.3 ), and use in specific populations ( 8.5 )] .

or blood clots. • using estrogen-alone may increase your chance of getting dementia, based on a study of women age 65 years of age and older. • do not use estrogens with progestogens to prevent heart disease, heart attacks, strokes or dementia. • using estrogens with progestogens may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots. • using estrogens with progestogens may increase your chance of getting dementia, based on a study of women age 65 years of age and older. • only one estrogen-alone product and dose have been shown to increase your chances of getting strokes, blood clots, and dementia. only one estrogen with progestogen product and dose have been shown to increase your chances of getting heart attacks, strokes, breast cancer, blood clots, and dementia. because other products and doses have not been studied in the same way, it is not known how the use of menostar will affect your chances of these conditions. you and your healthcare provider should talk regularly about whether you still need treatment with menostar. what is menostar? menostar is a prescription medicine patch (transdermal system) that contains estradiol (an estrogen hormone). what is menostar used for? menostar is used after menopause to: • help reduce your chances of getting osteoporosis (thin weak bones) osteoporosis from menopause is a thinning of the bones that makes them weaker and easier to break. if you use menostar only to prevent osteoporosis due to menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. you and your healthcare provider should talk regularly about whether you still need treatment with menostar. who should not use menostar? do not start using menostar if you: • have unusual vaginal bleeding vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). your healthcare provider should check any unusual vaginal bleeding to find out the cause. • have been diagnosed with a bleeding disorder • currently have or have had certain cancers estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus (womb). if you have or have had cancer, talk with your healthcare provider about whether you should use menostar. • had a stroke or heart attack • currently have or have had blood clots • currently have or have had liver problems • are allergic to menostar or any of the ingredients in it. see the list of ingredients in menostar at the end of this leaflet. before you use menostar, tell your healthcare provider about all of your medical conditions, including if you: • have any unusual vaginal bleeding vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). your healthcare provider should check any unusual vaginal bleeding to find out the cause. • have any other medical conditions that may become worse while you are using menostar your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, angioedema (swelling of face and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. • are going to have surgery or will be on bed rest your healthcare provider will let you know if you need to stop using menostar. • are pregnant or think you may be pregnant menostar is not for pregnant women. • are breastfeeding the hormone in menostar can pass into your breast milk. tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. some medicines may affect how menostar works. menostar may also affect how your other medicines work. keep a list of your medicines and show it to your healthcare provider and pharmacist when you get new medicine. how should i use menostar? for detailed instructions, see the step-by-step instructions for using menostar at the end of this patient information. • use menostar exactly as your healthcare provider tells you to use it. • menostar is for skin use only. • change your menostar patch 1 time each week or every 7 days. • apply your menostar patch to a clean, dry area on your lower abdomen or buttocks. this area must be clean, dry, and free of powder, oil or lotion for your patch to stick to your skin. • apply your menostar patch to a different area of your abdomen or your buttocks each time. do not use the same application site 2 times in the same week. • do not apply menostar to your breasts. • if you forget to apply a new menostar patch, apply a new patch as soon as possible. • you and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are using and whether you still need treatment with menostar. how to change menostar. • when changing menostar, peel off the used patch slowly from the skin. • after removal of menostar if any adhesive residue remains on your skin, allow the area to dry for 15 minutes. then, gently rub the area with an oil-based cream or lotion to remove the adhesive from your skin. • apply the new patch to a different area of your abdomen or buttocks. this area must be clean, dry, and free of powder, oil or lotion. do not use the same site again for at least 1 week after removal of an old patch. what are the possible side effects of menostar? side effects are grouped by how serious they are and how often they happen when you are treated. serious, but less common side effects include: call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: • new breast lumps • unusual vaginal bleeding • changes in vision or speech • sudden new severe headaches • severe pains in your chest or legs with or without shortness of breath, weakness and fatigue common side effects include: • headache • breast tenderness or pain • irregular vaginal bleeding or spotting • stomach or abdominal cramps, bloating • nausea and vomiting • hair loss • fluid retention • vaginal yeast infection • redness and/or irritation at the patch placement site these are not all the possible side effects of menostar. for more information, ask your healthcare provider or pharmacist. tell your healthcare provider if you have any side effects that bother you or do not go away. you may report side effects to fda at 1-800-fda-1088. you may report side effects to bayer healthcare pharmaceuticals at 1-888-842-2937. what can i do to lower my chances of a serious side effect with menostar? • talk with your healthcare provider regularly about whether you should continue using menostar. • if you have a uterus, talk with your healthcare provider about whether menostar is right for you. in general, the addition of a progestogen is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). • see your healthcare provider right away if you get vaginal bleeding while using menostar. • have a pelvic exam, breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. if members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often. • if you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances of getting heart disease. ask your healthcare provider for ways to lower your chances of getting heart disease. how should i store and throw away used menostar? • store menostar at room temperature 68°f to 77°f (20°c to 25°c). • do not store menostar patches outside of their pouches. apply immediately upon removal from the protective pouch. • used patches still contain estrogen. to throw away the patch, fold the sticky side of the patch together, place it in a sturdy child-proof container, and place this container in the trash. used patches should not be flushed in the toilet. keep menostar and all medicines out of the reach of children. general information about the safe and effective use of menostar. medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. do not use menostar for conditions for which it was not prescribed. do not give menostar to other people, even if they have the same symptoms you have. it may harm them. you can ask your healthcare provider or pharmacist for information about menostar that is written for health professionals. for more information, go to www.menostar-us.com or call bayer healthcare pharmaceuticals inc. at 1-888-842-2937. what are the ingredients in menostar? active ingredient: estradiol inactive ingredients: acrylate copolymer adhesive, fatty acid esters, and polyethylene backing. click or tap here to enter text. instructions for use menostar (mĕn-ō-stär) (estradiol transdermal system) read this patient information before you start using menostar and each time you get a refill. there may be new information. this information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. you will need the following supplies: see figure a figure a step 1: pick the days you will change your menostar. • you will need to change your patch 1 time each week or every 7 days. step 2. remove the menostar patch from the pouch. • remove the patch from its protective pouch by tearing at the notch (do not use scissors). see figure b • do not remove your patch from the protective pouch until you are ready to apply it. figure b step 3. remove the adhesive liner. see figure c • you will see that menostar is an oval shaped clear patch that is attached to a thick, hard-plastic adhesive liner and covered by a clear, plastic film. see figure c • to apply your patch you must first remove the protective, clear plastic film that is attached to the clear thicker plastic backing. see figure d • there is a silver foil-sticker attached to the inside of the pouch. do not remove the silver foil sticker from the pouch. see figure e figure c figure d figure e step 4. placing the patch on your skin. • apply the sticky side of the patch to 1 of the areas of skin shown below. see figure f and figure g • do not touch the sticky side of the patch with your fingers. figure f figure g note: • avoid the waistline, since clothing and belts may cause the patch to be rubbed off. • do not apply menostar to your breasts. • only apply menostar to skin that is clean, dry, and free of any powder, oil, or lotion. • do not apply the patch to injured, burned, or irritated skin, or areas with skin conditions (such as birth marks, tattoos, or that is very hairy). step 5. press the patch firmly onto your skin. • press the patch firmly in place with your fingers for at least 10 seconds. • rub the edges of the patch to make sure that it will stick to your skin. ( see figure h ) figure h note: • contact with water while you are swimming, using a sauna, bathing, or showering may cause the patch to fall off. • if your patch falls off reapply it. if you cannot reapply the patch, apply a new patch to another area (see figure f and figure g) and continue to follow your original application schedule. • if you stop using your menostar patch or forget to apply a new patch as scheduled, you may have spotting, or bleeding, or your symptoms may come back. step 6: throwing away your used patch. • when it is time to change your patch, remove the old patch before you apply a new patch. • to throw away the patch, fold the sticky side of the patch together, place it in a sturdy child-proof container, and place this container in the trash. used patches should not be flushed in the toilet. this patient information and instructions for use have been approved by the u.s food and drug administration. revised: 9/2021 © 2013, bayer healthcare pharmaceuticals inc. all rights reserved. manufactured for bayer healthcare pharmaceuticals inc. whippany, nj 07981 menostar pouch removal of pouch protective backing removal of backing removing patch front placement back placement press in place